MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 555991 | Name: Diosgenin palmitate
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Diosgenin palmitate, also known as Diosgenin hexadecanoate, is the hexadecanoic ester of Diosgenin. Diosgenin, a phytosteroid sapogenin, is the product of hydrolysis by acids, strong bases, or enzymes of saponins, extracted from the tubers of Dioscorea wild yam, such as the Kokoro. The sugar-free (aglycone) product of such hydrolysis, diosgenin is used for the commercial synthesis of cortisone, pregnenolone, progesterone, and other steroid products.

Chemical Structure

Diosgenin palmitate
Diosgenin palmitate
CAS#4952-66-3

Theoretical Analysis

MedKoo Cat#: 555991

Name: Diosgenin palmitate

CAS#: 4952-66-3

Chemical Formula: C43H72O4

Exact Mass: 652.5431

Molecular Weight: 653.05

Elemental Analysis: C, 79.09; H, 11.11; O, 9.80

Price and Availability

Size Price Availability Quantity
50mg USD 950.00 2 Weeks
100mg USD 1,650.00 2 Weeks
200mg USD 2,650.00 2 Weeks
500mg USD 3,650.00 2 Weeks
1g USD 4,650.00 2 Weeks
2g USD 7,650.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Diosgenin palmitate; Diosgenin hexadecanoate; Spirost-5-en-3β-ol, palmitate; Spirost-5-en-3-ol;
IUPAC/Chemical Name
(4S,5'R,6aR,6bS,8aS,8bR,9S,10R,11aS,12aS,12bS)-5',6a,8a,9-tetramethyl-1,3,3',4,4',5,5',6,6a,6b,6',7,8,8a,8b,9,11a,12,12a,12b-icosahydrospiro[naphtho[2',1':4,5]indeno[2,1-b]furan-10,2'-pyran]-4-yl palmitate
InChi Key
UTLFPCHHNIPLBC-PUYSEAGNSA-N
InChi Code
InChI=1S/C43H72O4/c1-6-7-8-9-10-11-12-13-14-15-16-17-18-19-39(44)46-34-23-25-41(4)33(28-34)20-21-35-36(41)24-26-42(5)37(35)29-38-40(42)32(3)43(47-38)27-22-31(2)30-45-43/h20,31-32,34-38,40H,6-19,21-30H2,1-5H3/t31-,32+,34+,35-,36+,37+,38+,40+,41+,42+,43-/m1/s1
SMILES Code
[H][C@]1(O[C@@]2(OC[C@H](C)CC2)[C@H]3C)C[C@@]4([H])[C@]5([H])CC=C6C[C@@H](OC(CCCCCCCCCCCCCCC)=O)CC[C@]6(C)[C@@]5([H])CC[C@]4(C)[C@]13[H]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Diosgenin palmitate, also known as Diosgenin hexadecanoate, is the hexadecanoic ester of Diosgenin.
In vitro activity:
In order to evaluate the potential of diosgenin as a direct RORγ inverse agonist, luciferase assays employing RORγ-Gal4 were performed. Thereby, diosgenin showed a potent and concentration-dependent inverse agonistic activity with a determined IC50 value of 1.73 µM, which is highly comparable to that of the described RORα/γ inverse agonist T0901317 (Figure 3). Reference: Biomedicines. 2022 Aug 25;10(9):2076. https://pubmed.ncbi.nlm.nih.gov/36140177/
In vivo activity:
The abnormal changes of mesangial matrix expansion, glomerular basement membrane (GBM) thickness, foot process (FP) width, urine albumin/creatinine (UACR), DESMIN, ADRP, NEPHRIN, PODOCIN, SIRT6 in Mod group were alleviated in DH (high dose of diosgenin) mouse group rather than DL (low dose of diosgenin) group in the first part of animal experiment. The effect in DH group could be reversed in DH+OSS group and the same effect was observed in MDL800 group in the second part of animal experiment. Diosgenin could protect against podocyte injury in early phase of diabetic nephropathy by regulating SIRT6. Reference: Phytomedicine. 2022 Sep;104:154276. https://pubmed.ncbi.nlm.nih.gov/35728388/

Preparing Stock Solutions

The following data is based on the product molecular weight 653.05 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Schwarz PF, Perhal AF, Schöberl LN, Kraus MM, Kirchmair J, Dirsch VM. Identification of the Natural Steroid Sapogenin Diosgenin as a Direct Dual-Specific RORα/γ Inverse Agonist. Biomedicines. 2022 Aug 25;10(9):2076. doi: 10.3390/biomedicines10092076. PMID: 36140177; PMCID: PMC9495423. 2. Lai Z, Wang H, Tang X, Zhang L, Wang T, Cheng J. Study on the Mechanism of Diosgenin Targeting STAT3 to Inhibit Colon Cancer Proliferation and Migration. Dis Markers. 2022 Jun 4;2022:7494887. doi: 10.1155/2022/7494887. PMID: 35698571; PMCID: PMC9188474. 3. Wang Z, Wu Q, Wang H, Gao Y, Nie K, Tang Y, Su H, Hu M, Gong J, Fang K, Dong H. Diosgenin protects against podocyte injury in early phase of diabetic nephropathy through regulating SIRT6. Phytomedicine. 2022 Sep;104:154276. doi: 10.1016/j.phymed.2022.154276. Epub 2022 Jun 13. PMID: 35728388. 4. Khateeb S, Albalawi A, Alkhedaide A. Diosgenin Modulates Oxidative Stress and Inflammation in High-Fat Diet-Induced Obesity in Mice. Diabetes Metab Syndr Obes. 2022 May 24;15:1589-1596. doi: 10.2147/DMSO.S355677. PMID: 35637860; PMCID: PMC9147404.
In vitro protocol:
1. Schwarz PF, Perhal AF, Schöberl LN, Kraus MM, Kirchmair J, Dirsch VM. Identification of the Natural Steroid Sapogenin Diosgenin as a Direct Dual-Specific RORα/γ Inverse Agonist. Biomedicines. 2022 Aug 25;10(9):2076. doi: 10.3390/biomedicines10092076. PMID: 36140177; PMCID: PMC9495423. 2. Lai Z, Wang H, Tang X, Zhang L, Wang T, Cheng J. Study on the Mechanism of Diosgenin Targeting STAT3 to Inhibit Colon Cancer Proliferation and Migration. Dis Markers. 2022 Jun 4;2022:7494887. doi: 10.1155/2022/7494887. PMID: 35698571; PMCID: PMC9188474.
In vivo protocol:
1. Wang Z, Wu Q, Wang H, Gao Y, Nie K, Tang Y, Su H, Hu M, Gong J, Fang K, Dong H. Diosgenin protects against podocyte injury in early phase of diabetic nephropathy through regulating SIRT6. Phytomedicine. 2022 Sep;104:154276. doi: 10.1016/j.phymed.2022.154276. Epub 2022 Jun 13. PMID: 35728388. 2. Khateeb S, Albalawi A, Alkhedaide A. Diosgenin Modulates Oxidative Stress and Inflammation in High-Fat Diet-Induced Obesity in Mice. Diabetes Metab Syndr Obes. 2022 May 24;15:1589-1596. doi: 10.2147/DMSO.S355677. PMID: 35637860; PMCID: PMC9147404.
1: Wu FC, Jiang JG. Effects of diosgenin and its derivatives on atherosclerosis. Food Funct. 2019 Nov 1;10(11):7022-7036. doi: 10.1039/c9fo00749k. Epub 2019 Nov 5. PMID: 31687707. 2: Sethi G, Shanmugam MK, Warrier S, Merarchi M, Arfuso F, Kumar AP, Bishayee A. Pro-Apoptotic and Anti-Cancer Properties of Diosgenin: A Comprehensive and Critical Review. Nutrients. 2018 May 19;10(5):645. doi: 10.3390/nu10050645. PMID: 29783752; PMCID: PMC5986524. 3: Gan Q, Wang J, Hu J, Lou G, Xiong H, Peng C, Zheng S, Huang Q. The role of diosgenin in diabetes and diabetic complications. J Steroid Biochem Mol Biol. 2020 Apr;198:105575. doi: 10.1016/j.jsbmb.2019.105575. Epub 2019 Dec 30. PMID: 31899316. 4: Parama D, Boruah M, Yachna K, Rana V, Banik K, Harsha C, Thakur KK, Dutta U, Arya A, Mao X, Ahn KS, Kunnumakkara AB. Diosgenin, a steroidal saponin, and its analogs: Effective therapies against different chronic diseases. Life Sci. 2020 Nov 1;260:118182. doi: 10.1016/j.lfs.2020.118182. Epub 2020 Aug 8. PMID: 32781063. 5: Cai B, Zhang Y, Wang Z, Xu D, Jia Y, Guan Y, Liao A, Liu G, Chun C, Li J. Therapeutic Potential of Diosgenin and Its Major Derivatives against Neurological Diseases: Recent Advances. Oxid Med Cell Longev. 2020 Mar 6;2020:3153082. doi: 10.1155/2020/3153082. PMID: 32215172; PMCID: PMC7079249. 6: Lian Y, Wen D, Meng X, Wang X, Li H, Hao L, Xue H, Zhao J. Inhibition of invadopodia formation by diosgenin in tumor cells. Oncol Lett. 2020 Dec;20(6):283. doi: 10.3892/ol.2020.12148. Epub 2020 Sep 23. PMID: 33014161; PMCID: PMC7520800. 7: Chen Y, Tang YM, Yu SL, Han YW, Kou JP, Liu BL, Yu BY. Advances in the pharmacological activities and mechanisms of diosgenin. Chin J Nat Med. 2015 Aug;13(8):578-87. doi: 10.1016/S1875-5364(15)30053-4. PMID: 26253490. 8: Jesus M, Martins AP, Gallardo E, Silvestre S. Diosgenin: Recent Highlights on Pharmacology and Analytical Methodology. J Anal Methods Chem. 2016;2016:4156293. doi: 10.1155/2016/4156293. Epub 2016 Dec 28. PMID: 28116217; PMCID: PMC5225340. 9: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Fenugreek. 2021 Feb 15. PMID: 30000838. 10: Nazir R, Kumar V, Gupta S, Dwivedi P, Pandey DK, Dey A. Biotechnological strategies for the sustainable production of diosgenin from Dioscorea spp. Appl Microbiol Biotechnol. 2021 Jan;105(2):569-585. doi: 10.1007/s00253-020-11055-3. Epub 2021 Jan 6. PMID: 33404834. 11: Bergeron MF, Mountjoy M, Armstrong N, Chia M, Côté J, Emery CA, Faigenbaum A, Hall G Jr, Kriemler S, Léglise M, Malina RM, Pensgaard AM, Sanchez A, Soligard T, Sundgot-Borgen J, van Mechelen W, Weissensteiner JR, Engebretsen L. International Olympic Committee consensus statement on youth athletic development. Br J Sports Med. 2015 Jul;49(13):843-51. doi: 10.1136/bjsports-2015-094962. PMID: 26084524. 12: Sahu P, Gidwani B, Dhongade HJ. Pharmacological activities of dehydroepiandrosterone: A review. Steroids. 2020 Jan;153:108507. doi: 10.1016/j.steroids.2019.108507. Epub 2019 Oct 3. PMID: 31586606. 13: Fuller S, Stephens JM. Diosgenin, 4-hydroxyisoleucine, and fiber from fenugreek: mechanisms of actions and potential effects on metabolic syndrome. Adv Nutr. 2015 Mar 13;6(2):189-97. doi: 10.3945/an.114.007807. PMID: 25770257; PMCID: PMC4352177. 14: Raju J, Mehta R. Cancer chemopreventive and therapeutic effects of diosgenin, a food saponin. Nutr Cancer. 2009;61(1):27-35. doi: 10.1080/01635580802357352. PMID: 19116873. 15: Bucci LR. Selected herbals and human exercise performance. Am J Clin Nutr. 2000 Aug;72(2 Suppl):624S-36S. doi: 10.1093/ajcn/72.2.624S. PMID: 10919969. 16: Li X, Liu S, Qu L, Chen Y, Yuan C, Qin A, Liang J, Huang Q, Jiang M, Zou W. Dioscin and diosgenin: Insights into their potential protective effects in cardiac diseases. J Ethnopharmacol. 2021 Jun 28;274:114018. doi: 10.1016/j.jep.2021.114018. Epub 2021 Mar 11. PMID: 33716083. 17: Abarikwu SO, Onuah CL, Singh SK. Plants in the management of male infertility. Andrologia. 2020 Apr;52(3):e13509. doi: 10.1111/and.13509. Epub 2020 Jan 28. PMID: 31989693. 18: Gong J, Fang K, Dong H, Wang D, Hu M, Lu F. Effect of fenugreek on hyperglycaemia and hyperlipidemia in diabetes and prediabetes: A meta-analysis. J Ethnopharmacol. 2016 Dec 24;194:260-268. doi: 10.1016/j.jep.2016.08.003. Epub 2016 Aug 2. PMID: 27496582. 19: Xia N, Li H. The role of perivascular adipose tissue in obesity-induced vascular dysfunction. Br J Pharmacol. 2017 Oct;174(20):3425-3442. doi: 10.1111/bph.13650. Epub 2016 Nov 17. PMID: 27761903; PMCID: PMC5610151. 20: Santos HO, Howell S, Teixeira FJ. Beyond tribulus (Tribulus terrestris L.): The effects of phytotherapics on testosterone, sperm and prostate parameters. J Ethnopharmacol. 2019 May 10;235:392-405. doi: 10.1016/j.jep.2019.02.033. Epub 2019 Feb 18. PMID: 30790614.